ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1401

Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study

George A Karpouzas1, Zoltan Szekanecz2, Eva Baecklund3, Ted Mikuls4, Deepak L Bhatt5, Harry Shi6, Cunshan Wang7, Gosford A Sawyerr8, Yan Chen6, Sujatha Menon7, Carol A Connell7, Steven R Ytterberg9 and Mahta Mortezavi8, 1Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, 2Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary, 3Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 4Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 5Department of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 6Pfizer, Inc, Collegeville, PA, 7Pfizer Inc, Groton, CT, 8Pfizer Inc, New York, NY, 9Division of Rheumatology, Mayo Clinic, Rochester, MN

Meeting: ACR Convergence 2022

Keywords: Anti-TNF Drugs, Disease Activity, Disease-Modifying Antirheumatic Drugs (Dmards), rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Uncontrolled RA activity and acute disease flares are associated with higher risk of adverse outcomes, such as cardiovascular (CV) disease, venous thromboembolism (VTE), malignancy, and infection.1-4 Here, we evaluate associations of acute and cumulative Clinical Disease Activity Index (CDAI) measurements with CV, malignancy, or infectious adverse events (AEs) of interest in ORAL Surveillance.

Methods: ORAL Surveillance (NCT02092467) was a post-authorization safety study of tofacitinib vs TNF inhibitors (TNFi) in patients aged ≥ 50 years with active RA despite MTX and ≥ 1 additional CV risk factor. Patients were randomized 1:1:1 to receive tofacitinib 5 or 10 mg twice daily (BID) or subcutaneous TNFi. Two post hoc analyses were performed: (1) a time-varying multi-variable Cox model examining risks of AEs of interest when patients were in CDAI-defined low ( > 2.8–≤ 10; LDA), moderate ( > 10–≤ 22; MDA), or high ( > 22; HDA) disease activity vs remission ( ≤ 2.8), and including patient demographics, medical history, RA characteristics, prior treatments, baseline medications, and treatment arm, pre-selected using backward selection, and (2) calculation of area under the curve (AUC)/year for CDAI prior to event or to study end (patients without events) and comparison using analysis of variance with treatment arm, event status, and interaction between the two (supportive). Nominal p values were generated.

Results: A total of 4,362 patients were included. Mean RA duration at baseline was approximately 10 years. All patients were on MTX at baseline, and 28% had previously been on one other synthetic DMARD. Overall, 10% of patients had been on one biologic DMARD. Hazard ratios suggested that when patients had LDA, MDA, or HDA vs remission, they were potentially at higher risk of developing major adverse CV events (MACE), VTE, and non‑serious infections (NSIs; excluding herpes zoster [HZ]), but not malignancies, serious infections, or HZ (Fig). Similarly, mean CDAI AUC trended higher for MACE, VTE, and NSIs for patients with events (Table).

Conclusion: In ORAL Surveillance, the risk of MACE, VTE, and NSIs excluding HZ, was higher when patients had active disease vs remission. Greater cumulative RA disease activity was seen in patients with these AEs vs those without. Our findings support treat‑to-target recommendations for RA.

1. Molander et al. Ann Rheum Dis 2021; 80: 169-75

2. Maradit-Kremers et al. Arthritis Rheum 2005; 52: 722-32

3. Au et al. Ann Rheum Dis 2011; 70: 785-91

4. Baecklund et al. Arthritis Rheum 2006; 54: 692-701

Study sponsored by Pfizer. Medical writing support was provided by K Thompson, CMC Connect, and funded by Pfizer.

Supporting image 1

Supporting image 2


Disclosures: G. Karpouzas, Janssen, Sanofi-Genzyme-Regeneron, Pfizer Inc; Z. Szekanecz, AbbVie, Eli Lilly, Novartis, Pfizer Inc, Roche, Sanofi, Gedeon Richter; E. Baecklund, None; T. Mikuls, Gilead Sciences, Bristol-Myers Squibb, Horizon, Sanofi, Pfizer Inc; D. Bhatt, Pfizer Inc; H. Shi, Pfizer Inc; C. Wang, Pfizer Inc; G. Sawyerr, Syneos Health Inc, Pfizer Inc; Y. Chen, Pfizer Inc; S. Menon, Pfizer Inc; C. Connell, Pfizer Inc; S. Ytterberg, Corbus Pharmaceuticals, Kezar Life Sciences, Pfizer Inc; M. Mortezavi, Pfizer Inc.

To cite this abstract in AMA style:

Karpouzas G, Szekanecz Z, Baecklund E, Mikuls T, Bhatt D, Shi H, Wang C, Sawyerr G, Chen Y, Menon S, Connell C, Ytterberg S, Mortezavi M. Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/relationship-between-disease-activity-and-adverse-events-of-interest-in-patients-with-ra-on-tofacitinib-or-tnf-inhibitors-post-hoc-analysis-of-a-phase-3b-4-randomized-safety-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/relationship-between-disease-activity-and-adverse-events-of-interest-in-patients-with-ra-on-tofacitinib-or-tnf-inhibitors-post-hoc-analysis-of-a-phase-3b-4-randomized-safety-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology